Eliem Therapeutics Stock Current Valuation
| ELYMDelisted Stock | USD 5.16 0.09 1.78% |
Valuation analysis of Eliem Therapeutics helps investors to measure Eliem Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Eliem Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Eliem Therapeutics is based on 3 months time horizon. Increasing Eliem Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Eliem stock is determined by what a typical buyer is willing to pay for full or partial control of Eliem Therapeutics. Since Eliem Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eliem Stock. However, Eliem Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.16 | Real 5.13 | Hype 5.09 | Naive 4.37 |
The intrinsic value of Eliem Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eliem Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eliem Therapeutics helps investors to forecast how Eliem stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eliem Therapeutics more accurately as focusing exclusively on Eliem Therapeutics' fundamentals will not take into account other important factors: Eliem Therapeutics Company Current Valuation Analysis
Eliem Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Eliem Therapeutics Current Valuation | 122.66 M |
Most of Eliem Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eliem Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Eliem Therapeutics has a Current Valuation of 122.66 M. This is 99.15% lower than that of the Biotechnology sector and 97.36% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.26% higher than that of the company.
Eliem Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eliem Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eliem Therapeutics could also be used in its relative valuation, which is a method of valuing Eliem Therapeutics by comparing valuation metrics of similar companies.Eliem Therapeutics is currently under evaluation in current valuation category among its peers.
Eliem Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 122.66 M | |||
| Shares Outstanding | 67.06 M | |||
| Shares Owned By Insiders | 10.38 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 1.15 M | |||
| Price To Book | 1.56 X | |||
| EBITDA | (40.27 M) | |||
| Net Income | (35.12 M) | |||
| Cash And Equivalents | 122.95 M | |||
| Cash Per Share | 4.63 X | |||
| Total Debt | 349 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 17.48 X | |||
| Book Value Per Share | 3.33 X | |||
| Cash Flow From Operations | (20.6 M) | |||
| Short Ratio | 4.07 X | |||
| Earnings Per Share | (2.22) X | |||
| Target Price | 4.5 | |||
| Beta | -0.35 | |||
| Market Capitalization | 346.03 M | |||
| Total Asset | 110.47 M | |||
| Retained Earnings | (155.98 M) | |||
| Working Capital | 107.42 M | |||
| Net Asset | 110.47 M |
About Eliem Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eliem Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eliem Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eliem Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |